Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cardiac safety biomarkers

Executive Summary

Biomarkers of cardiac and drug-induced injury will be discussed by the FDA Pharmaceutical Science Advisory Committee/Nonclinical Studies Subcommittee Sept. 9-10. The subcommittee will consider reports from its expert working groups: the cardiotoxicity biomarker working group is preparing a position paper recommending the use of cardiac troponins as a biomarker of cardiac injury (1"The Pink Sheet" Nov. 19, 2001, p. 8). Potential transfer of oversight of the subcommittee to the National Center for Toxicological Research's Science Advisory Board will also be revisited at the meeting. The meeting will be at 5630 Fishers Lane, Rockville, Md., at 1:30 p.m. on Sept. 9 and 8 a.m. on Sept. 10...

You may also be interested in...



FDA Cardiotoxicity Group Paper To Suggest Use Of Troponins As Biomarkers

FDA's cardiotoxicity biomarker working group is preparing a position paper recommending the use of cardiac troponins as a biomarker of cardiac injury

Amgen/AstraZeneca’s Tezepelumab Cuts Asthma Exacerbations By 56%

Data presented at AAAI meeting show reduced annualized asthma exacerbation rates across all patient populations, but doctors are unlikely to switch patients served well by existing biologics. 

Sarepta’s Next-Generation Drugs Draw Attention Amid ‘Incremental’ Approval

The RNA drug’s accelerated approval brings Sarepta’s exon-skipping market share to nearly 30%.

UsernamePublicRestriction

Register

IV001392

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel